Company news

Rakovina Therapeutics Inc news in 2025

Rakovina Therapeutics Inc's news releases, calls and decks from 2025, newest first.

View company

Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California

December 17, 2025

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

December 10, 2025

Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update

December 1, 2025

Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program

November 28, 2025

Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting

November 24, 2025

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

November 24, 2025

Rakovina Therapeutics' President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit

November 18, 2025

Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

November 10, 2025

Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference

October 27, 2025

Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference

October 16, 2025

Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 4, 2025

Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update

August 28, 2025

Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis

August 26, 2025

Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies

August 12, 2025

Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre

July 30, 2025

Rakovina Therapeutics Announces Stock Option Grants

July 29, 2025

Rakovina Therapeutics Announces Warrant Exercise Incentive Program

July 24, 2025

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

July 23, 2025

Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access

July 15, 2025

Rakovina Therapeutics Congratulates Partner - Variational AI for Winning LifeSciencesBC's 2025 Emerging Biotech Company of the Year Award

July 11, 2025

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

July 10, 2025

Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

June 30, 2025

Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025

June 30, 2025

Rakovina Therapeutics Announces Results from 2025 Annual General Meeting

June 25, 2025

Rakovina Therapeutics Announces Share Consolidation Effective Date

June 20, 2025

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

June 12, 2025

Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

June 6, 2025

Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update

June 2, 2025

Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

May 28, 2025

Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation

May 15, 2025

Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer

May 5, 2025

Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update

April 30, 2025

Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel

April 29, 2025

Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025

April 29, 2025

Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery

April 22, 2025

Rakovina Therapeutics Unveils Preclinical Data at the AACR - World's Premier Cancer Research Forum

March 25, 2025

Next-Gen Cancer Treatment: Rakovina's AI-Driven ATR Inhibitors Enter Preclinical Testing

March 12, 2025

Rakovina Therapeutics and Variational AI Strengthen Partnership

February 26, 2025

Decks in 2025